Unknown

Dataset Information

0

MTORC1 promotes survival through translational control of Mcl-1.


ABSTRACT: Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a frequent occurrence in human cancers and a major promoter of chemotherapeutic resistance. Inhibition of one downstream target in this pathway, mTORC1, has shown potential to improve chemosensitivity. However, the mechanisms and genetic modifications that confer sensitivity to mTORC1 inhibitors remain unclear. Here, we demonstrate that loss of TSC2 in the E mu-myc murine lymphoma model leads to mTORC1 activation and accelerated oncogenesis caused by a defective apoptotic program despite compromised AKT phosphorylation. Tumors from Tsc2(+/-)E mu-Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin. We identified myeloid cell leukemia sequence 1 (Mcl-1), a bcl-2 like family member, as a translationally regulated genetic determinant of mTORC1-dependent survival. Our results indicate that the extent by which rapamycin can modulate expression of Mcl-1 is an important feature of the rapamycin response.

SUBMITTER: Mills JR 

PROVIDER: S-EPMC2504845 | biostudies-other | 2008 Aug

REPOSITORIES: biostudies-other

altmetric image

Publications

mTORC1 promotes survival through translational control of Mcl-1.

Mills John R JR   Hippo Yoshitaka Y   Robert Francis F   Chen Samuel M H SM   Malina Abba A   Lin Chen-Ju CJ   Trojahn Ulrike U   Wendel Hans-Guido HG   Charest Al A   Bronson Roderick T RT   Kogan Scott C SC   Nadon Robert R   Housman David E DE   Lowe Scott W SW   Pelletier Jerry J  

Proceedings of the National Academy of Sciences of the United States of America 20080729 31


Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a frequent occurrence in human cancers and a major promoter of chemotherapeutic resistance. Inhibition of one downstream target in this pathway, mTORC1, has shown potential to improve chemosensitivity. However, the mechanisms and genetic modifications that confer sensitivity to mTORC1 inhibitors remain unclear. Here, we demonstrate that loss of TSC2 in the E mu-myc murine lymphoma model leads to mTORC1 activation and  ...[more]

Similar Datasets

| S-EPMC6117477 | biostudies-literature
2017-06-19 | GSE65409 | GEO
| S-EPMC3907335 | biostudies-literature
| S-EPMC8473834 | biostudies-literature
| S-EPMC4396488 | biostudies-literature
2017-02-11 | GSE94801 | GEO
| S-EPMC8313533 | biostudies-literature